After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Xenon Pharmaceuticals Inc is $3.48B. A total of 0.3 million shares were traded on the day, compared to an average of 812.65K shares.
In the most recent transaction, MORTIMER IAN sold 14,375 shares of XENE for 45.03 per share on Dec 05 ’25. After the transaction, the PRESIDENT & CEO now owns 16,830 company shares. In a previous transaction on Dec 08 ’25, MORTIMER IAN sold 10,830 shares at 45.73 per share. XENE shares that PRESIDENT & CEO owns now total 6,000.
Among the insiders who bought shares, IAN MORTIMER acquired of 10,830 shares on Dec 08 ’25 at a per-share price of $45.73. In another insider transaction, IAN MORTIMER bought 14,375 shares at $45.03 per share on Dec 05 ’25.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, XENE has a high of $46.60 and a low of $26.74.
As of this writing, XENE has an earnings estimate of -$1.2 per share for the current quarter. EPS was calculated based on a consensus of 13.0 estimates, with a high estimate of -$1.1 per share and a lower estimate of -$1.38. The company reported an EPS of -$0.84 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. XENE’s latest balance sheet shows that the firm has $551.77M in Cash & Short Term Investments as of fiscal 2021. There were $8.26M in debt and $14.32M in liabilities at the time. Its Book Value Per Share was $7.26, while its Total Shareholder’s Equity was $550.03M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XENE is Buy with a score of 4.81.
